STOCK TITAN

Nurix Therapeutics: Deep Track reports 5.49% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. (NRIX) is the issuer in an amendment where Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin each report beneficial ownership of 6,000,000 common shares, or 5.49% of the class.

Each reports shared voting and dispositive power over 6,000,000 shares and zero sole voting or dispositive power. The identical reported positions are not additive. The percentage is based on 109,249,814 common shares outstanding as of September 30, 2026.

Beneficial ownership 6,000,000 shares Reported by each reporting person as of September 30, 2026; identical reported positions are not additive.
Percent of class 5.49% Based on common shares outstanding as of September 30, 2026.
Common shares outstanding 109,249,814 shares As of September 30, 2026.
beneficially owned regulatory
"Aggregate amount beneficially owned by each reporting person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power regulatory
"Shared voting power: 6,000,000"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared dispositive power: 6,000,000"
joint filing statement regulatory
"Joint filing statement pursuant to Rule 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NRIX shares do Deep Track and David Kroin report owning?

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin each report beneficial ownership of 6,000,000 Nurix common shares, equal to 5.49% of the class. Each reports shared voting and dispositive power over 6,000,000 shares and zero sole voting or dispositive power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





67080M103

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Deep Track Capital, LP
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:11/16/2026
Deep Track Biotechnology Master Fund, Ltd.
Signature:/s/ David Kroin
Name/Title:David Kroin, Director
Date:11/16/2026
David Kroin
Signature:/s/ David Kroin
Name/Title:David Kroin
Date:11/16/2026
Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of September 30, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 109,249,814 Common Stock outstanding as of September 30, 2026, according to the issuer's 10-Q filed with the SEC on October 13, 2026. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

Keep reading